{"id":55917,"date":"2026-01-30T13:56:06","date_gmt":"2026-01-30T05:56:06","guid":{"rendered":"https:\/\/flcube.com\/?p=55917"},"modified":"2026-01-30T13:56:07","modified_gmt":"2026-01-30T05:56:07","slug":"cspcs-sys-6055-car-t-gets-nmpa-nod-for-lymphoma-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55917","title":{"rendered":"CSPC&#8217;s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials"},"content":{"rendered":"\n<p><strong>CSPC Pharmaceutical Group Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1093:HKG\">HKG:\u202f1093<\/a>) announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has approved a clinical trial for <strong>SYS 6055<\/strong>, the <strong>first in vivo CAR\u2011T therapy<\/strong> approved for trials in China, for the treatment of <strong>relapsed\/refractory aggressive B\u2011cell lymphoma<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-technology-innovation\">Regulatory Milestone &amp; Technology Innovation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>CSPC Pharmaceutical Group Ltd (HKEX:\u202f01093)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>SYS 6055<\/td><\/tr><tr><td><strong>Approval<\/strong><\/td><td>NMPA clinical trial authorization<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Relapsed\/refractory aggressive B\u2011cell lymphoma<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>In vivo chimeric antigen receptor (CAR)\u2011T therapy<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Lentiviral vector generates CD19\u2011targeted CAR\u2011T cells within the body<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>First in vivo CAR\u2011T therapy approved for trials in China<\/td><\/tr><tr><td><strong>Key Advantages<\/strong><\/td><td>Cost, accessibility, and timeliness vs. traditional ex vivo CAR\u2011T<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-preclinical-data\">Drug Profile &amp; Preclinical Data<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism of Action:<\/strong> Utilizes a <strong>lentiviral vector<\/strong> to directly generate CD19\u2011targeted CAR\u2011T cells <strong>in vivo<\/strong>, enabling specific recognition and elimination of malignant B cells<\/li>\n\n\n\n<li><strong>Preclinical Validation:<\/strong> Demonstrated ability to specifically generate CAR\u2011T cells in vivo, with <strong>significant tumor suppression effects<\/strong> and a <strong>favorable safety profile<\/strong><\/li>\n\n\n\n<li><strong>Competitive Edge:<\/strong> Compared with traditional CAR\u2011T products requiring complex ex vivo manufacturing, SYS 6055 offers potential advantages in <strong>cost reduction, broader patient accessibility, and faster treatment initiation<\/strong><\/li>\n\n\n\n<li><strong>Market Position:<\/strong> First\u2011in\u2011class in China for in vivo CAR\u2011T approach, addressing critical gaps in B\u2011cell lymphoma treatment<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>B\u2011Cell Lymphoma Burden:<\/strong> <strong>~100,000 new aggressive B\u2011cell lymphoma cases<\/strong> annually in China; <strong>30\u201140%<\/strong> become relapsed\/refractory to frontline therapy<\/li>\n\n\n\n<li><strong>CAR\u2011T Market Growth:<\/strong> China\u2019s CAR\u2011T cell therapy market projected to reach <strong>\u00a515\u202fbillion<\/strong> (~US$2\u202fbillion) by 2030, driven by expanding indications and patient access<\/li>\n\n\n\n<li><strong>Cost Advantage:<\/strong> In vivo manufacturing could reduce treatment costs by <strong>50\u201170%<\/strong> versus traditional CAR\u2011T, expanding addressable patient population beyond current reimbursement limits<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts estimate <strong>\u00a5800\u202fmillion\u20131.5\u202fbillion<\/strong> (US$110\u2013210\u202fmillion) peak annual sales potential if approved, based on premium pricing and first\u2011mover advantage<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Positions CSPC as pioneer in next\u2011generation cell therapy; validates proprietary lentiviral platform for future pipeline expansion<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Phase\u202fI trial initiation expected <strong>Q2\u202f2026<\/strong>; early efficacy and safety data anticipated <strong>H1\u202f2027<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, market potential, and regulatory pathways for SYS 6055. Actual results may differ due to clinical trial outcomes, competitive dynamics, and NMPA review processes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CSPC Pharmaceutical Group Ltd (HKG:\u202f1093) announced that the National Medical Products Administration (NMPA) has approved&#8230;<\/p>\n","protected":false},"author":1,"featured_media":55919,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,21,77,62,171,855],"class_list":["post-55917","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-car-t","tag-cell-therapy","tag-clinical-trial-approval-initiation","tag-cspc-pharmaceutical","tag-hkg-1093"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC&#039;s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CSPC Pharmaceutical Group Ltd (HKG:\u202f1093) announced that the National Medical Products Administration (NMPA) has approved a clinical trial for SYS 6055, the first in vivo CAR\u2011T therapy approved for trials in China, for the treatment of relapsed\/refractory aggressive B\u2011cell lymphoma.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55917\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC&#039;s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials\" \/>\n<meta property=\"og:description\" content=\"CSPC Pharmaceutical Group Ltd (HKG:\u202f1093) announced that the National Medical Products Administration (NMPA) has approved a clinical trial for SYS 6055, the first in vivo CAR\u2011T therapy approved for trials in China, for the treatment of relapsed\/refractory aggressive B\u2011cell lymphoma.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55917\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-30T05:56:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-30T05:56:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3012.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55917#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55917\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC&#8217;s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials\",\"datePublished\":\"2026-01-30T05:56:06+00:00\",\"dateModified\":\"2026-01-30T05:56:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55917\"},\"wordCount\":391,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55917#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3012.webp\",\"keywords\":[\"Cancer\",\"CAR-T\",\"Cell-therapy\",\"Clinical trial approval \\\/ initiation\",\"CSPC Pharmaceutical\",\"HKG: 1093\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55917#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55917\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55917\",\"name\":\"CSPC's SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55917#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55917#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3012.webp\",\"datePublished\":\"2026-01-30T05:56:06+00:00\",\"dateModified\":\"2026-01-30T05:56:07+00:00\",\"description\":\"CSPC Pharmaceutical Group Ltd (HKG:\u202f1093) announced that the National Medical Products Administration (NMPA) has approved a clinical trial for SYS 6055, the first in vivo CAR\u2011T therapy approved for trials in China, for the treatment of relapsed\\\/refractory aggressive B\u2011cell lymphoma.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55917#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55917\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55917#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3012.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3012.webp\",\"width\":1080,\"height\":608,\"caption\":\"CSPC's SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55917#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC&#8217;s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC's SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials - Insight, China&#039;s Pharmaceutical Industry","description":"CSPC Pharmaceutical Group Ltd (HKG:\u202f1093) announced that the National Medical Products Administration (NMPA) has approved a clinical trial for SYS 6055, the first in vivo CAR\u2011T therapy approved for trials in China, for the treatment of relapsed\/refractory aggressive B\u2011cell lymphoma.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55917","og_locale":"en_US","og_type":"article","og_title":"CSPC's SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials","og_description":"CSPC Pharmaceutical Group Ltd (HKG:\u202f1093) announced that the National Medical Products Administration (NMPA) has approved a clinical trial for SYS 6055, the first in vivo CAR\u2011T therapy approved for trials in China, for the treatment of relapsed\/refractory aggressive B\u2011cell lymphoma.","og_url":"https:\/\/flcube.com\/?p=55917","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-30T05:56:06+00:00","article_modified_time":"2026-01-30T05:56:07+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3012.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55917#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55917"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC&#8217;s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials","datePublished":"2026-01-30T05:56:06+00:00","dateModified":"2026-01-30T05:56:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55917"},"wordCount":391,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=55917#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3012.webp","keywords":["Cancer","CAR-T","Cell-therapy","Clinical trial approval \/ initiation","CSPC Pharmaceutical","HKG: 1093"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55917#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55917","url":"https:\/\/flcube.com\/?p=55917","name":"CSPC's SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=55917#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=55917#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3012.webp","datePublished":"2026-01-30T05:56:06+00:00","dateModified":"2026-01-30T05:56:07+00:00","description":"CSPC Pharmaceutical Group Ltd (HKG:\u202f1093) announced that the National Medical Products Administration (NMPA) has approved a clinical trial for SYS 6055, the first in vivo CAR\u2011T therapy approved for trials in China, for the treatment of relapsed\/refractory aggressive B\u2011cell lymphoma.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55917#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55917"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=55917#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3012.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3012.webp","width":1080,"height":608,"caption":"CSPC's SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55917#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC&#8217;s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3012.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55917","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55917"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55917\/revisions"}],"predecessor-version":[{"id":55920,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55917\/revisions\/55920"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/55919"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55917"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55917"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55917"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}